Press Release

October 29, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400051 Mumbai- 400001 (SYMBOL: THYROCARE) (SCRIP CODE: 539871) Sub: Press Release on Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026 Ref: Disclosure under Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/ Madam, Please find enclosed - the Press Release on the unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026. The same is also being made available on the Company’s website https://investor.thyrocare.com/ We request you to please take the same on record. Yours Faithfully, For Thyrocare Technologies Limited, Brijesh Kumar Company Secretary and Compliance Officer Encl. A/a NEWS Release Thyrocare Technologies Limited reports revenue of INR 270.8 Cr in Q2FY27 with a growth of 25.1% YoY Revenue EBITDA PAT before Exceptions INR 270.8 Cr INR 89.3 Cr INR 60.2 Cr 25.1% YoY 24.9% YoY 25.7% YoY Navi Mumbai, October 29, 2026 Thyrocare Technologies Limited (hereinafter referred to as “Thyrocare” NSE: THYROCARE, BSE: 539871), a leading healthcare diagnostics company, today announced its results for the quarter ended September 30, 2026. From Routine to Remarkable: The Next Frontier of Diagnostics • The most exciting part of this year’s journey is specialty. We took the Thyrocare playbook of scale, reach and affordability into specialty diagnostics, starting with allergy and genomics, and the business is now live and gaining steady traction. We call this journey - From Routine to Remarkable - The next frontier of Diagnostics. • Thyrocare launches Pregnancy Test Kit, a rapid home-testing solution that delivers results in just five minutes and backed by a confirmatory lab test. We have onboarded actress Yami Gautam as our brand ambassador to strengthen awareness and consumer outreach for this product. We have launched this with the help of our API Holdings group company Ascent and are already present in more than 10,000 chemists. Key Financial Highlights for Q2FY27 • Consolidated revenue registered a 25.1% year-on-year growth, driven primarily by a 26.7% increase in the Pathology segment. • In the Pathology business, franchise revenue grew by 26.9% year-on-year, while partnership revenue recorded 27.9% year-on-year growth. • Thyrocare, India’s largest diagnostic test volume processor, processed 61.6 million tests in Q2FY27, marking a strong 27.4% year-on-year growth and reinforcing its volume leadership position in the industry. • Consolidated EBITDA grew by 24.9% year-on-year to Rs 89.3 Cr, and Profit After Tax (PAT) before exceptional items grew by 25.7% year-on-year to Rs 60.2 Cr • The exceptional item represents a one-time, non-cash impairment charge of Rs 45 Cr relating to NHL in consolidated books, recognised in connection with the definitive term sheet for the sale of the NHL business. This charge does not impact the Company’s operational performance. • Sustained Six Sigma quality standards, reducing complaints per million tests to 2.90 (down 24% YoY) with ATAT at 3.49 hours. Thyrocare Reports Strong Q2FY27 Results – Revenue Up 25.1%, PAT before Exceptional Items Up 25.7% The Company delivered a robust performance in Q2FY27, with consolidated revenue of ₹270.8 crore, up 25.1% year-on-year, led by continued momentum in the Pathology segment, which grew 26.7% YoY. EBITDA rose 24.9% YoY to ₹89.3 crore. PAT before exceptional items surged 25.7% YoY to ₹60.2 crore, underscoring the Company’s focus on profitable growth. Exceptional items comprise a one-time, non-cash impairment charge of ₹45 crore relating to NHL, recognised in the consolidated financial statements in connection with the definitive term sheet for the proposed sale of the NHL business. This charge has no impact on the Company’s operational performance. Thyrocare has issued a postal ballot seeking shareholders’ approval for the proposed divestment of its Nuclear Imaging business, enabling the Company to sharpen its focus and allocate capital towards its Pathology business, which offers a stronger growth trajectory, higher margins and better return on capital employed (ROCE). Thyrocare, India’s largest diagnostic test volume processor, further strengthened its leadership position during the quarter, processing 61.6 million tests, up 27.4% year-on-year. The Pathology business maintained strong traction, with franchise revenue up 26.9% and partnership revenue up 27.9% year-on-year. Thyrocare’s commitment to quality continued to deliver Six Sigma-level performance, with complaints reduced to 2.9 per million (down 24% YoY) and an average turnaround time (ATAT) of 3.49 hours from sample receipt. Thyrocare continued its expansion into specialty diagnostics, marking the next phase of its growth journey. Having commenced with allergy and genomics, the Company is progressively expanding its specialty test portfolio, with a focus on building clinical trust through scientific rigour, uncompromising quality and industry-leading turnaround times. Thyrocare also launched its Pregnancy Test Kit, a rapid home-testing solution that delivers results in just five minutes and is the first kit in India backed by a confirmatory lab test. The Company has onboarded actress Yami Gautam as brand ambassador to strengthen awareness and consumer outreach for this product. We have launched this with the help of our API Holdings group company Ascent and are already present in more than 10,000 chemists. Senior management remarks: “Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India. I am particularly excited about our foray into Point of Care devices with a unique proposition and soon hope to be present in all major chemist outlets.” –Rahul Guha, MD & CEO, Thyrocare Technologies Ltd Consolidated Financial Performance for Q2FY27 P a rtic u la rs IN R c ro re R e v e n u e fro m o p e ra tio n s C o s t o f m a te ria ls c o n s u m e d / s o ld G ro s s m a rg in E m p lo y e e b e n e fit e x p e n s e s O th e r e x p e n s e s R e p o rte d E B IT D A D e p re c ia tio n a n d a m o rtis a tio n F in a n c e c o s t O th e r in c o m e P B T a n d e x c e p tio n a l ite m s S h a re o f p ro fit in a s s o c ia te e n tity E x c e p tio n a l Ite m s T a x e x p e n s e R e p o rte d P A T P A T b e fo re e x c e p tio n s R e p o rte d E P S (IN R ) E P S b e fo re e x c e p tio n s (IN R ) G ro s s m a rg in % R e p o rte d E B IT D A % R e p o rte d P A T % P A T b e fo re e x c e p tio n s % Q 2 F Y 2 2 7 0 .8 -6 9 .8 2 0 1 .0 -4 5 .2 -6 6 .5 8 9 .3 -1 3 .5 -1 .6 3 .6 7 7 .8 0 .8 -4 5 .0 -1 8 .4 1 5 .2 6 0 .2 0 .9 6 3 .7 8 7 4 .2 % 3 3 .0 % 5 .6 % 2 2 .2 % Q u a rte Q 1 F Y 2 2 4 0 .0 -6 2 .2 1 7 7 .9 -3 9 .6 -6 1 .0 7 7 .3 -1 2 .5 -1 .4 4 .2 6 7 .6 0 .7 0 .0 -1 7 .0 5 1 .3 5 1 .3 3 .2 3 3 .2 3 7 4 .1 % 3 2 .2 % 2 1 .4 % 2 1 .4 % 7 Q 2 F Y 2 2 1 6 .5 -6 0 .1 1 5 6 .5 -3 3 .1 -5 1 .9 7 1 .5 -1 1 .5 -0 .6 3 .1 6 2 .4 0 .3 0 .0 -1 4 .8 4 7 .9 4 7 .9 3 .0 1 3 .0 1 7 2 .3 % 3 3 .0 % 2 2 .1 % 2 2 .1 % G ro w th .1 % .4 % .9 % .7 % .7 % .6 % H 1 F Y 2 5 1 0 .8 -1 3 2 .0 3 7 8 .8 -8 4 .8 -1 2 7 .5 1 6 6 .6 -2 6 .0 -2 .9 7 .8 1 4 5 .4 1 .5 -4 5 .0 -3 5 .4 6 6 .6 1 1 1 .5 4 .1 8 7 .0 1 7 4 .2 % 3 2 .6 % 1 3 .0 % 2 1 .8 % lf y e a r H 1 F Y 2 4 0 9 .6 -1 1 [Showing first 8,000 characters — download PDF for full document]